Favipiravir is one of the few potential coronavirus drugs launched or waiting to be launched in the market. It is used to treat the coronavirus affected patients having mild to moderate symptoms. The drug is now dragged into a price war with several other firms involved in the same business looking towards launching the oral antiviral tablet in the market
Glenmark Pharma, a company located in Mumbai was behind the launch of this drug. In June the tablet was made public with a price tag of Rs. 103 per tablet. Recently the price has been revised to Rs 79 per tablet. This week only, Pune’s Brinton Pharma has received permits for the tablets. This firm has priced the same at Rs 59 per tablet. Now, what is interesting is that Jenburkt Pharma, another Mumbai based company, has made it available only for a mere sum of Rs 39 per tablet.
According to rumors traveling in the industry, several other brands are lined up for launch, including one from the leading pharma firm Cipla. As a result, a high degree of competition is expected to volunteer in the market.
Jenburkt is making favipiravir with the brand name Favivent in Telangana. The state has a pharmaceutical plant that is compliant with the US Food and Drug Administration or USFDA. The drug would be made available for consumption in the form of 10 tablets per strip.
The Drug Controller General of India or DCGI has already approved the use of favipiravir earlier this year. With the nod, the medication which is an antiviral drug developed in Japan and is commonly used for treating influenza is now all set to be used for the treatment of mild to moderate cases of Covid-19 in the country. Favipiravir is a broad-spectrum antiviral agent. The drug selectively inhibits RNA polymerase of influenza virus and prevents viral replication.